| Name | Title | Contact Details |
|---|
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast as possible. The needs of people living with rare diseases are at the center of our inventive science, our commercial organization, and our clinical programs. Every member of the Amicus Therapeutics team works to make a meaningful difference for the communities that we serve. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our global footprint spans 27 countries, including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain.
Ambulatory Cardiac Monitoring | Mobile Cardiac Telemetry, Holter, Extended Holter & Wireless Event | Implantable Monitoring Service | Helping physicians add quality years to patients lives, ONE patient at a time.
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Odan Laboratories is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.